



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

On October 9, 2001

TOWNSEND and TOWNSEND and CREW LLP

By:

Rosamarie L. Celli
Rosamarie L. Celli

PATENT
Attorney Docket No.: 15270J-004741US
Client Ref. No.: 209-US-CIP5C1

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of:

SCHENK, Dale B.

Application No.: 09/723,713

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Unassigned

NOV 08 2001

Art Unit: 1647

TECH CENTER 1600/2900

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant submits herewith the required paper copy of the Sequence Listing. Applicant has concurrently filed Request To Reference Previously Filed Identical Computer Readable Copy According To 37 CFR 1.821(e); and, therefore, Applicant has not submitted computer readable copy of the sequence listing herewith.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows:

Please replace the paragraph beginning at line 23 of page 11 with the following paragraph.

B1 H₂N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-
Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-
Val-Val-Ile-Ala-OH. (SEQ ID NO:1)

Please replace the paragraph beginning at line 12 of page 50 with the following paragraph.

A β 1-12 peptide	NH ₂ -DAEFRHDSGYEV <u>C</u> -COOH (SEQ ID NO:2)
A β 1-5 peptide	NH ₂ -DAEF <u>R</u> <u>C</u> -COOH (SEQ ID NO:3)
A β 33-42 peptide	NH ₂ - <u>C</u> -amino-heptanoic acid-GLMVGGVVIA-COOH (SEQ ID NO:4)
A β 13-28 peptide	Ac-NH-HHQKLVFFAEDVGSNK <u>GGC</u> -COOH (SEQ ID NO:5)

B2 Please replace the paragraph beginning at line 30 of page 83 with the following paragraph.

B3 Two different APP assays were utilized. The first, designated APP- α /FL, recognizes both APP-alpha (α) and full-length (FL) forms of APP. The second assay is specific for APP- α . The APP- α /F assay recognizes secreted APP including the first 12 amino acids of A β . Since the reporter antibody (2H3) is not specific to the α -clip-site, occurring between amino acids 612-613 of APP695 (Esch et al., Science 248, 1122-1124 (1990)); this assay also recognizes full length APP (APP-FL). Preliminary experiments using immobilized APP antibodies to the cytoplasmic tail of APP-FL to deplete brain homogenates of APP-FL suggest that approximately 30-40% of the APP- α /FL APP is FL (data not shown). The capture antibody for both the APP- α /FL and APP- α assays is mAb 8E5, raised against amino acids 444 to 592 of the APP695 form (Games et al., supra). The reporter mAb for the APP- α /FL assay is mAb 2H3, specific for amino acids 597-608 of APP695 (Johnson-Wood et al., supra) and the reporter antibody for the APP- α assay is a biotinylated derivative of mAb 16H9, raised to amino acids 605 to 611 of APP. The lower limit of sensitivity of the APP- α FL assay is about 11 ng/ml (150 pM) (Johnson-Wood et al.) and that of the APP- α specific assay is 22 ng/ml (0.3 nM). For both APP assays, mAb 8E5 was coated onto the wells of 96-well EIA plates as described above for mAb 266. Purified, recombinant secreted APP- α was used as the reference standard for the